[TALK 10] Biophysics in Drug Discovery - Dillon Rinauro

Value of the Information & Strength of the Argument

The talk provides valuable insights into the practical application of biophysics in an industrial drug discovery setting. It offers a comprehensive overview of the drug discovery pipeline and clearly articulates where biophysics fits in, which is useful for both newcomers and experienced researchers. The argumentation is solid, supported by concrete examples from AstraZeneca’s projects. The speaker explains the rationale behind choosing certain techniques for specific questions, highlighting the strengths and limitations of each method. For instance, he discusses how SPR is sensitive and practical for fragment screening, while NMR provides solution-phase binding information and structural clues. He also addresses challenges such as weak binding affinities of fragments and the need for orthogonal validation. The talk is well-structured, moving logically from general concepts to specific case studies, and effectively demonstrates the value of biophysics in reducing attrition and improving decision-making.

Scientific Rigor, Source Quality, Title Accuracy

The talk is scientifically rigorous, with the speaker demonstrating a deep understanding of the biophysical techniques and their applications. He provides detailed explanations of the methods, including their principles and practical considerations. The sources cited are primarily internal to AstraZeneca, but he also references literature and publicly available information. The description includes links to AstraZeneca’s R&D page and the LMB’s website, which are relevant. The title accurately reflects the content, as the talk is indeed about biophysics in drug discovery. There is no obvious discrepancy between the title and the content. The speaker’s expertise and the institutional backing from AstraZeneca and the MRC LMB lend credibility to the information presented.

The title accurately reflects the content, as the talk focuses on the role of biophysics in drug discovery, presented by Dillon Rinauro.

8/10

The talk is given by a senior scientist from AstraZeneca's biophysics team, providing a detailed and practical overview of biophysics applications in drug discovery. The content is based on real project examples and demonstrates a strong understanding of the techniques. While not peer-reviewed, the speaker's expertise and the institutional context lend credibility. The presentation is clear and well-structured, with specific case studies that illustrate the points.

Markers derived by PSI from the transcript: the creator did not define chapters.

• 00:00Introduction and overview of the talk
• 02:00Drug discovery process overview and attrition rates
• 05:00Stages of drug discovery: target identification, hit identification, hit-to-lead, lead optimization, preclinical, clinical
• 10:00Where biophysics contributes: reagent characterization, hit identification, orthogonal validation, mechanistic characterization
• 15:00Overview of biophysical techniques at AstraZeneca: SPR, NMR, native MS, HDX, ITC, mass photometry, FIDA
• 20:00Reagent characterization: native mass spectrometry for co-factor removal
• 25:00Reagent characterization: HDX for protein disorder assessment
• 30:00Reagent characterization: ITC for binding affinity and stoichiometry
• 35:00Hit identification: fragment screening with SPR and NMR
• 40:00SPR principles and immobilization methods
• 45:00Case studies: overcoming potency limits, molecular glues
• 50:00Summary and conclusions

• AstraZeneca R&D — Referenced as the company's R&D page for further information.
• MRC Laboratory of Molecular Biology — The host institution's official site.
• LMB YouTube Playlist — Link to the series of talks.

• AstraZeneca R&D — The speaker's employer, providing context for the industrial perspective.

• www.linkedin.com
• www.youtube.com